We are live on
!
Find out more
EAM
Empery Asset Management Portfolio holdings
AUM
$86.5M
This Fund
S&P 500
This Quarter
Est. Return
-21.02%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.3M
AUM Growth
-$26.6M
(-56%)
Cap. Flow
-$16.7M
Cap. Flow
% of AUM
-78.3%
Top 10 Holdings %
Top 10 Hldgs %
66.69%
Holding
94
New
24
Increased
–
Reduced
32
Closed
17
Avg Time Held
0.7
quarters
Top 10 Avg Time Held
0.4
quarters
Top 20 Avg Time Held
0.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TCBPW
TC BioPharm (Holdings) plc Warrants
TCBPW
|
+$1.31M |
| 2 |
Sunshine Biopharma
SBFM
|
+$1.12M |
| 3 |
BRC Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock a
BRCC.WS
|
+$855K |
| 4 |
VLNS
The Valens Company, Inc. Common Shares
VLNS
|
+$854K |
| 5 |
Soleno Therapeutics
SLNO
|
+$484K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iSpecimen
ISPC
|
+$3.64M |
| 2 |
OHAA
OPY Acquisition Corp. I Class A Common Stock
OHAA
|
+$2.96M |
| 3 |
AMPE
Ampio Pharmaceuticals Inc.
AMPE
|
+$2.43M |
| 4 |
RNERU
Mount Rainier Acquisition Corp. Unit
RNERU
|
+$2.03M |
| 5 |
Cactus Acquisition Corp. 1 Limited Unit
CCTSU
|
+$2.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 74.67% |
| 2 | Healthcare | 19.72% |
| 3 | Technology | 3.09% |
| 4 | Consumer Staples | 1.98% |
| 5 | Energy | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
POL.WS
1
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
| $5.13M | 24.13% |
8,295,355
-153,900
| -2% | -$123K |
2021 Q4
1 quarter
|
|
|
TCBPW
2
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
| $1.38M | 6.5% |
+2,823,528
| New | +$1.31M |
2022 Q1
0 quarters
|
|
|
FATBW
3
DELISTED
FAT Brands Inc. Warrant
FATBW
| $1.27M | 5.95% |
281,598
-18,402
| -6% | -$109K |
2021 Q4
1 quarter
|
|
|
4
DELISTED
BRC Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock a
BRCC.WS
| $1.2M | 5.65% |
+269,212
| New | +$855K |
2022 Q1
0 quarters
|
|
|
5
Sunshine Biopharma
SBFM
$1.31M
| $1.1M | 5.19% |
+23
| New | +$1.12M |
2022 Q1
0 quarters
|
|
|
HCDIZ
6
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIZ
| $1.08M | 5.09% |
2,930,730
-69,270
| -2% | -$30.3K |
2021 Q4
1 quarter
|
|
7
Surrozen
SRZN
$349M
| $1M | 4.72% |
22,264
-16,449
| -42% | -$813K |
2021 Q4
1 quarter
|
|
|
VLNS
8
DELISTED
The Valens Company, Inc. Common Shares
VLNS
| $688K | 3.23% |
+400,000
| New | +$854K |
2022 Q1
0 quarters
|
|
|
ZEV.WS
9
DELISTED
Lightning eMotors, Inc. Redeemable Warrants, each whole warrant exercisable 1/20th of a share of common stock at an exercise price of $230.00 per whole share
ZEV.WS
| $663K | 3.12% |
676,381
-19,271
| -3% | -$18.9K |
2021 Q4
1 quarter
|
|
10
AIOS Tech
AIOS
$37.1M
| $658K | 3.09% |
3,363
-1,588
| -32% | -$432K |
2021 Q4
1 quarter
|
|
11
DELISTED
Nutriband Inc Warrant
NTRBW
| $581K | 2.73% |
76,604
-3,396
| -4% | -$11.4K |
2021 Q4
1 quarter
|
|
12
DELISTED
Hagerty, Inc. Warrants, each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share
HGTY.WS
| $522K | 2.45% |
178,758
-8,742
| -5% | -$37.7K |
2021 Q4
1 quarter
|
|
13
Starling Oncology
STLN
$676M
| $504K | 2.37% |
70,733
-129,267
| -65% | -$872K |
2021 Q4
1 quarter
|
|
14
DELISTED
Reeds, Inc. Common Stock
REED
| $421K | 1.98% |
+28,000
| New | +$433K |
2022 Q1
0 quarters
|
|
15
BNB Standard Corporation Warrant
BNCWW
| $335K | 1.57% |
+500,000
| New | +$261K |
2022 Q1
0 quarters
|
|
|
16
DELISTED
Soleno Therapeutics
SLNO
| $313K | 1.47% |
+93,427
| New | +$484K |
2022 Q1
0 quarters
|
|
|
CALA
17
DELISTED
Calithera Biosciences, Inc
CALA
| $313K | 1.47% |
+38,796
| New | +$396K |
2022 Q1
0 quarters
|
|
|
PEPLW
18
DELISTED
PepperLime Health Acquisition Corporation Warrrant
PEPLW
| $308K | 1.45% |
742,500
| – | – |
2021 Q4
1 quarter
|
|
19
DELISTED
SurgePays, Inc. Warrant
SURGW
| $255K | 1.2% |
286,495
-13,505
| -5% | -$10.2K |
2021 Q4
1 quarter
|
|
|
20
Sunshine Biopharma Inc Warrant
SBFMW
| $233K | 1.1% |
+235,200
| New | +$164K |
2022 Q1
0 quarters
|
|
21
Cingulate Inc Warrants
CINGW
| $200K | 0.94% |
500,000
| – | – |
2021 Q4
1 quarter
|
|
22
DELISTED
Direct Digital Holdings, Inc. Warrant
DRCTW
| $194K | 0.91% |
+270,000
| New | +$152K |
2022 Q1
0 quarters
|
|
23
DELISTED
Arbe Robotics Warrant
ARBEW
| $187K | 0.88% |
189,904
-10,096
| -5% | -$10.3K |
2021 Q4
1 quarter
|
|
24
DELISTED
Worksport, Ltd. Warrant
WKSPW
| $143K | 0.67% |
193,370
-6,630
| -3% | -$4.92K |
2021 Q4
1 quarter
|
|
25
DELISTED
Lexaria Bioscience Warrant
LEXXW
| $118K | 0.55% |
130,682
-2,651
| -2% | -$2.99K |
2021 Q4
1 quarter
|
|
Similar funds
BCM
TI
LCM
AA
RCSA
YAG
CL
TWM
Empery Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Empery Asset Management held 94 positions worth $21.3M, down 56% from $47.9M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Empery Asset Management withdrew a net $16.7M in Q1 2022, closing 17 positions and reducing 32 holdings. Its most notable exit was iSpecimen, an estimated $3.64M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 75% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Empery Asset Management opened a new position in TC BioPharm (Holdings) plc Warrants worth $1.38M.
- Empery Asset Management's largest Q1 2022 buy was TC BioPharm (Holdings) plc Warrants: 2,823,528 shares worth $1.38M.
- Empery Asset Management's biggest Q1 2022 reduction was Starling Oncology, cutting an estimated $872K.
- Empery Asset Management fully exited iSpecimen in Q1 2022, selling an estimated $3.64M.
- Empery Asset Management's ten largest holdings make up 67% of its $21.3M portfolio in Q1 2022.
- Empery Asset Management opened 24 new positions and closed 17 in Q1 2022.
- Empery Asset Management's portfolio value fell 56% quarter-over-quarter to $21.3M.
Based on Empery Asset Management's 13F filing for Q1 2022, filed 16 May 2022.